Retrospective multicenter nested case-control safety study of Ilaprazole sodium for injection

LI Jin; FANG Rende; SONG Juan; ZHANG Yongzhou; ZHANG Fan; ZHAO Qun; CAI Suhua; ZHANG Yi; HU Haitang; DENG Jianxiong

doi:10.6039/j.issn.1001-0408.2023.11.18

您当前的位置：

首页 >

文章列表页 >

Retrospective multicenter nested case-control safety study of Ilaprazole sodium for injection

更新时间：2023-06-09

- Retrospective multicenter nested case-control safety study of Ilaprazole sodium for injection
- ZHONGGUO YAOFANG Vol. 34, Issue 11, Pages: 1379-1383(2023)
- 作者机构：
  
  1.广州和睦家医院药剂科，广州　510335
  2.广东省药理学会，广州　510080
  3.丽珠医药集团股份有限公司，广东珠海　519000
  4.河南大学淮河医院药剂科，河南开封　475000
  5.聊城市人民医院药剂科，山东聊城　252000
  6.淄博市中心医院药剂科，山东淄博　255036
  7.广州中医药大学金沙洲医院药剂科，广州　510168
  8.东莞康华医院药剂科，广东东莞　523080
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.11.18
  CLC： R975;R969
- Published：15 June 2023，
  
  Received：27 November 2022，
  
  Revised：07 May 2023，
扫描看全文
李晋,方壬德,宋娟等.注射用艾普拉唑钠的回顾性多中心巢式病例对照安全性研究 ^Δ[J].中国药房,2023,34(11):1379-1383.

LI Jin,FANG Rende,SONG Juan,et al.Retrospective multicenter nested case-control safety study of Ilaprazole sodium for injection[J].ZHONGGUO YAOFANG,2023,34(11):1379-1383.
李晋,方壬德,宋娟等.注射用艾普拉唑钠的回顾性多中心巢式病例对照安全性研究 ^Δ[J].中国药房,2023,34(11):1379-1383. DOI： 10.6039/j.issn.1001-0408.2023.11.18.

LI Jin,FANG Rende,SONG Juan,et al.Retrospective multicenter nested case-control safety study of Ilaprazole sodium for injection[J].ZHONGGUO YAOFANG,2023,34(11):1379-1383. DOI： 10.6039/j.issn.1001-0408.2023.11.18.

摘要

目的

了解注射用艾普拉唑钠在临床实际应用中的安全性。

方法

通过中国医院药物警戒系统收集5家三级医院2019年1月1日至2020年2月29日使用注射用艾普拉唑钠的住院患者共3 926例的病历资料，采用回顾性多中心单队列研究对注射用艾普拉唑钠进行上市后安全性分析；同时采用巢式病例对照研究（试验组与对照组按1∶4比例匹配）来证实本研究队列基线的稳定性，以及不良反应与注射用艾普拉唑钠的相关性。

结果

3 926例患者中，3例患者使用注射用艾普拉唑钠后共发生了5次不良事件，不良事件发生率为0.076%，无严重不良事件，发生时间均为用药2 d后；不良事件以肝功能指标（丙氨酸转氨酶、天冬氨酸转氨酶、总胆红素）升高为主，均为轻度且未处理，所有不良事件转归均为好转。巢式病例对照研究结果显示，试验组与对照组属于同一背景基线，不良事件的发生与注射用艾普拉唑钠相关性更大。

结论

注射用艾普拉唑钠整体安全性较高，不良事件的发生与其相关性更大。

Abstract

OBJECTIVE

To understand the safety of Ilaprazole sodium for injection in clinical practice.

METHODS

From Jan. 1st 2019 to Feb. 29th 2020， the data of 3 926 valid hospitalized patients receiving Ilaprazole sodium for injection were collected prospectively from 5 third-level hospitals through CHPS， and the post-marketing safety analysis was performed by using retrospective multicenter single cohort study. At the same time， a nested case-control study （the ratio of trial group and control group was 1∶4） was used to confirm the baseline stability of this study cohort and the correlation between adverse reactions and Ilaprazole sodium for injection.

RESULTS

Among 3 926 patients， 3 patients experienced 5 adverse drug events after using Ilaprazole sodium for injection， with the incidence of 0.076%. There was no serious adverse event， and the occurrence time was 2 days after medication； adverse drug events mainly include elevated liver function indicators （alanine transaminase， aspartate transaminase， total bilirubin）， which were mild and untreated， and all adverse drug events were improved. The results of the nested case-control study showed that the trial group and the control group belonged to the same background baseline， and the occurrence of adverse drug events was more closely related to Ilaprazole sodium for injection.

CONCLUSIONS

The overall safety of Ilaprazole sodium for injection is relatively high， and the occurrence of adverse events is more related to it.

关键词

注射用艾普拉唑钠回顾性研究巢式病例对照安全性研究药品不良反应药品不良事件

Keywords

retrospective studynested case-controlsafety studyadverse drug reactionadverse drug events

references

WANG L，ZHOU L Y，LIN S R，et al. A new PPI，ilaprazole compared with omeprazole in the treatment of duodenal ulcer：a randomized double-blind multicenter trial[J]. J Clin Gastroenterol，2011，45（4）：322-329.

JIA R R，ZHANG F，WU N，et al. Accelerating development of benziamidazole-class proton pump inhibitors：a mechanism-based PK/PD model to optimize study design with ilaprazole as a case drug[J]. Pharmaceutics，2021，13（3）：392.

CHO H，CHOI M K，CHO D Y，et al. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor，ilaprazole[J]. J Clin Pharmacol，2012，52（7）：976-984.

DU Y Q，GUO W Y，ZOU D W，et al. Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers：an open randomized cross-over study[J]. J Dig Dis，2012，13（2）：113-119.

武红莉，王刚，闫充岱，等. 养心氏片上市后多中心安全性评价[J]. 药物评价研究，2016，39（6）：1061-1065.

陈静静，钱佩佩，曹凯，等. 我国药品不良反应关联性评价方法与诺氏评估量表法的对比与分析[J]. 中国药事，2020，34（8）：988-992.

XUE Y，QIN X H，ZHOU L Y，et al. A randomized，double-blind，active-controlled，multi-center study of ilaprazole in the treatment of reflux esophagitis[J]. Clin Drug Investig，2016，36（12）：985-992.

LI F，QIN X H，WANG L，et al. Ilaprazole compared with rabeprazole in the treatment of duodenal ulcer：a randomi- zed，double-blind，active-controlled，multicenter study[J]. J Clin Gastroenterol，2019，53（9）：641-647.

LI H，XIA X J，ZHANG L F，et al. Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection：a prospective randomized study[J]. Eur J Gastroenterol Hepatol，2021，32（2）：194-200.

JIN Y，ZHANG S H，PAN J M，et al. Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis[J]. Pharmazie，2019，74（7）：432-438.

YOON Y H，PARK K W，LEE S H，et al. Efficacy of three proton-pump inhibitor therapeutic strategies on laryngopharyngeal reflux disease； a prospective randomized double-blind study[J]. Clin Otolaryngol，2019，44（4）：612-618.

CHAN F K，WONG V W，SUEN B Y，et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk：a double-blind，randomised trial[J]. Lancet，2007，369（9573）：1621-1626.

KUIPERS E J，SUNG J J，BARKUN A，et al. Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding[J]. Adv Ther，2011，28（2）：150-159.

XUE Y，QIN X H，ZHOU L Y，et al. A randomized，double blind，controlled，multi center study of ilaparazole in the treatment of reflux esophagitis：phase Ⅲ clinical trial[J]. Contemp Clin Trials，2018，68：67-71.

WANG L，ZHOU L Y，HU H T，et al. Ilaprazole for the treatment of duodenal ulcer：a randomized，double-blind and controlled phase Ⅲ trial[J]. Curr Med Res Opin，2012，28（1）：101-109.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

药学监护对2 型糖尿病患者出院后用药的影响

我院同一药品多发药品不良反应/事件报告分析

阿托西班防治早产的药品不良反应/事件文献分析

双黄连注射剂致27例患者死亡文献分析

抗感染药致药源性肝损伤572例分析

Related Author

李妍高玉霞刘丽亚赵霞李宏建苏乐群

葛云

谢静文薛　静谢咏湘

熊运珍雷招宝

朱曼?郭代红?史录文?韩晟?任昭?蔡乐?凡超?陈超?马亮?徐元杰

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰